Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2016

Open Access 01-12-2016 | Research

Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study

Authors: Sabrina Dewes, Kilian Schiller, Katharina Sauter, Matthias Eiber, Tobias Maurer, Markus Schwaiger, Jürgen E. Gschwend, Stephanie E. Combs, Gregor Habl

Published in: Radiation Oncology | Issue 1/2016

Login to get access

Abstract

Background

Prostate cancer (PC) is one of the most commonly treated cancer entities with radiation therapy (RT). Risk group-adapted treatment and avoidance of unnecessary toxicities relies primarily on accurate tumor staging. Thus, the introduction of prostate-specific membrane antigen (PSMA) in diagnosis and treatment of PC is a highly interesting development in radiation oncology of urologic tumors. The present work is to evaluate the integration of 68Ga-PSMA-PET imaging into standard radiation planning of primary definitive treatment of PC and to determine the impact of PSMA imaging on tumor staging.

Methods

The data of 15 patients treated for PC between August 2013 and April 2015 were evaluated. Treatment planning included 68Ga-PSMA-PET imaging. We analyzed whether the use of PSMA-imaging led to a change of the TNM stage and if it influenced the RT treatment approach or the target volume, due to changes in the gross tumor volume (GTV) or clinical target volume (CTV), in the final treatment plan.

Results

In 53.3 % of the analyzed patients a change occurred in the TNM stage based on 68Ga-PSMA-PET examination. The RT concept changed in 33.3 % of all patients, leading to relevant changes in the planning target volume. Among these, an additional irradiation of the pelvic lymph drainage due to tracer uptake in lymph nodes was performed in 25 %. Furthermore, boost volumes of PET-positive lymph nodes were added in 80 % of these cases. A down staging due to the 68Ga-PSMA-PET examination occurred in 13.3 % of all cases.

Conclusions

The integration of 68Ga-PSMA-PET-imaging into the RT treatment planning process can be useful for detailed target volume planning. The performance of a 68Ga-PSMA-PET frequently leads to changes in the TNM stage, altering the RT treatment regimen and the target volume. A prospective trial is underway to evaluate the impact of 68Ga-PSMA-PET based treatment planning on outcome.
Literature
1.
World Health Organization. Cancer mortality and morbidity. 2008.
2.
Robert Koch Institut Bundesamt. Prostataerkrankungen - Heft 36. Gesundheitsberichterstattung des Bundes. Januar 2007
3.
Leitlinie Onkologie. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. 2. Aktualisierung - Oktober 2014; Version 2.0 – 2. Aktualisierung - Oktober 2014 (AWMF-Register-Nummer (034-022OL)).
4.
Bundschuh RA, Wendl CM, Weirich G, Eiber M, Souvatzoglou M, Treiber U, Kubler H, Maurer T, Gschwend JE, Geinitz H, Grosu AL, Ziegler SI, Krause BJ. Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging. 2013;40(6):824–31. doi:10.​1007/​s00259-013-2345-7. Epub 2013/02/08.CrossRefPubMed
5.
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Kubler H, Haberkorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74. doi: 10.2967/jnumed.115.154153. Epub 2015 Mar 19.CrossRefPubMed
6.
Maurer T, Beer AJ, Wester HJ, Kubler H, Schwaiger M, Eiber M. Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? Int J Urol. 2014;21(12):1286–8. doi:10.​1111/​iju.​12577. Epub 2014/07/23.CrossRefPubMed
7.
Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–39.CrossRefPubMed
8.
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett J, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167–72. doi: 10.1007/s12253-008-9104-2. Epub 2008 Sep 18.CrossRefPubMed
9.
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart H, Hadaschik B, Holland-Letz T, Giesel F, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95. doi: 10.1007/s00259-012-2298-2. Epub 2012 Nov 24.CrossRefPubMed
10.
Silver DA, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.PubMed
11.
Afshar-Oromieh A, Avtzi E, Giesel F, Holland-Letz T, Linhart H, Eder M, Eisenhut M, Boxler S, Hadaschik B, Kratochwil K, Weichert W, Kopka K, Debus J, Haberkorn U. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209. doi: 10.1007/s00259-014-2949-6. Epub 2014 Nov 20.
12.
Eder M, Neels O, Muller M, Bauder-Wust U, Remde Y, Schafer M, Hennrich U, Eisenhut M, Afshar-Oromieh A, Haberkorn U, Kopka K. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals (Basel). 2014;7(7):779–96. doi: 10.3390/ph7070779.CrossRef
13.
Martin R, Juttler S, Muller M, Wester HJ. Cationic eluate pretreatment for automated synthesis of [(6)(8)Ga]CPCR4.2. Nucl Med Biol. 2014;41(1):84-9. doi: 10.1016/j.nucmedbio.2013.09.002. Epub 2013 Oct 9.CrossRefPubMed
14.
Schafer M, Bauder-Wust U, Leotta K, Zoller F, Mier W, Haberkorn U, Eisenhut M, Eder M. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012;2(1):23. doi: 10.1186/2191-219X-2-23.CrossRefPubMedPubMedCentral
15.
National Comprehensive Cancer Network. Guidelines on prostate cancer: National Comprehensive Cancer Network; 2014
16.
Roach 3rd M, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28(1):33–7. Epub 1994/01/01.CrossRefPubMed
17.
AJCC/UICC. AJCC Cancer Staging Manual. New York: Springer; 2010. p. 457.
18.
19.
Maurer T GJ, Wester HJ, Souvatzoglou M, Beer AJ, Holzapfel K, Wierich G, Haller B, Kübler H, Schwaiger M, Eiber M. PET imaging with prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA. ASCO 20152015.
20.
Afshar-Oromieh A, Zechmann C, Malcher A, Eder M, Eisenhut M, Linhart H, Holland-Letz T, Hadaschik B, Giesel F, Debus J, Haberkorn U. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. doi: 10.1007/s00259-013-2525-5. Epub 2013 Sep 27.CrossRefPubMedPubMedCentral
21.
Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, Kubler H, Thalgott M, Navab N, Schwaiger M, Wester HJ, Gschwend JE, Eiber M. Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. Eur Urol. 2015;68(3):530–4. doi: 10.1016/j.eururo.2015.04.034.CrossRefPubMed
22.
Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol. 2016;69(3):393–6. doi: 10.1016/j.eururo.2015.06.010.CrossRefPubMed
23.
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kuebler H, Beer AJ, Schwaiger M, Eiber M. Diagnostic Efficacy of 68-Gallium-PSMA Positron Emission Tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43. doi: 10.1016/j.juro.2015.12.025. Epub 2015 Dec 9.CrossRefPubMed
24.
Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-(68Ga(HBED-CC)) versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(12):1794–800. doi: 10.1007/s00259-015-3106-6.CrossRefPubMedPubMedCentral
25.
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256–61.CrossRefPubMed
26.
Hovels AM, Heesakkers R, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387–95. doi: 10.1016/j.crad.2007.05.022. Epub 2008 Feb 4.CrossRefPubMed
27.
Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18 F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64(1):106-17. doi: 10.1016/j.eururo.2013.04.019. Epub 2013 Apr 19.CrossRefPubMed
28.
Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013;63(6):1040–8. doi:10.​1016/​j.​eururo.​2012.​09.​039. Epub 2012/10/06.CrossRefPubMed
29.
Husarik DB, Miralbell R, Dubs M, John H, Giger O, Gelet A, Cservenyak T, Hany TF. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(2):253–63. Epub 2007 Oct 10.CrossRefPubMed
30.
Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011;12(2):181–91. doi: 10.1016/S1470-2045(10)70103-0. Epub 2010 Jul 6.CrossRefPubMed
31.
Ross JS, Sheehan C, Fisher H, Kaufman RJ, Kaur P, Gray K, Webb I, Gray G, Mosher R, Kallakury BV. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9(17):6357–62.PubMed
Metadata
Title
Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
Authors
Sabrina Dewes
Kilian Schiller
Katharina Sauter
Matthias Eiber
Tobias Maurer
Markus Schwaiger
Jürgen E. Gschwend
Stephanie E. Combs
Gregor Habl
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2016
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-016-0646-2

Other articles of this Issue 1/2016

Radiation Oncology 1/2016 Go to the issue

Reviewer acknowledgement

Radiation Oncology reviewer acknowledgement 2015

Research

Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH)

Research

Accelerated hyperfractionation plus temozolomide in glioblastoma

Research

Intrafractional dose variation and beam configuration in carbon ion radiotherapy for esophageal cancer

Research

The dosimetric impact of implants on the spinal cord dose during stereotactic body radiotherapy

Research

Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03)